Applicability of a structure-based modelling approach as a tool for in silico screening of oligonucleotides for targeted RNA editing presented at Oligonucleotide Therapeutics Society (OTS) 2018 by Julien Boudet
… the Netherlands, Feb. 28, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced results for … stable in CF mucus: During the 12th Annual Meeting of the OligonucleotideTherapeuticsSociety (OTS) September 25 – 28, 2016 the company presented a …
… CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company … $104.1 million. Delivered two presentations at the OligonucleotideTherapeuticsSociety (OTS) conference on clinical data for QR-110 in …
… the Netherlands, Nov. 14, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … the review process. During the 12 th Annual Meeting of the OligonucleotideTherapeuticsSociety (OTS) September 25 – 28, 2016 the company presented a …
… interim data also expected in 2018. Spin-out of Amylon Therapeutics as a privately-held company focused on central … Axiomer ® RNA editing technology platform at the OligonucleotideTherapeuticsSociety (OTS) meeting in Bordeaux, France and at the Drug …
